Panacea Index Logo

Command Palette

Search for a command to run...

Daily mycoprotein consumption for 1 week does not affect insulin sensitivity or glycaemic control but modulates the plasma lipidome in healthy adults: a randomised controlled trial.

The British journal of nutrition
January 28, 2021
Mariana O C Coelho et al. (6 authors)
Journal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine the impact of substituting meat/fish with mycoprotein on insulin sensitivity, glycaemic control, and plasma lipoprotein composition in healthy adults.

Results Summary

Mycoprotein did not affect insulin sensitivity or glycaemic control but led to a coordinated reduction in circulating cholesterol-containing lipoproteins, including decreases in total plasma cholesterol, LDL-cholesterol, and HDL2-cholesterol.

Population

Twenty healthy adults.

Effective Dosage

Mycoprotein was consumed twice daily (lunch and dinner) as the primary protein source.

Duration

7 days.

Interactions

None mentioned.

Extracted Claims (17)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Mycoprotein consumption
decrease
acute postprandial glycaemic control
-
-
has been shown to improve
#1
Mycoprotein consumption
decrease
circulating cholesterol concentrations
-
-
decrease
#2
incorporating mycoprotein into the diet
no change
blood glucose responses
Twenty healthy adults
no significant change
no changes
#3
incorporating mycoprotein into the diet
no change
serum insulin responses
Twenty healthy adults
no significant change
no changes
#4
incorporating mycoprotein into the diet
no change
insulin sensitivity (IS)
Twenty healthy adults
no significant change
no changes
#5
incorporating mycoprotein into the diet
no change
24 h glycaemic profiles
Twenty healthy adults
no significant change
no changes
#6
mycoprotein (MYC) as the primary source of dietary protein
decrease
Forty-five lipid concentrations of different lipoprotein fractions (VLDL, LDL, intermediate-density lipoprotein and HDL)
MYC group
7-27 %
showed a coordinated decrease
#7
mycoprotein (MYC) as the primary source of dietary protein
decrease
Total plasma cholesterol
MYC group
14-19 %
decreased to a larger degree
#8
mycoprotein (MYC) as the primary source of dietary protein
decrease
free cholesterol
MYC group
14-19 %
decreased to a larger degree
#9
mycoprotein (MYC) as the primary source of dietary protein
decrease
LDL-cholesterol
MYC group
14-19 %
decreased to a larger degree
#10
mycoprotein (MYC) as the primary source of dietary protein
decrease
HDL2-cholesterol
MYC group
14-19 %
decreased to a larger degree
#11
mycoprotein (MYC) as the primary source of dietary protein
decrease
DHA
MYC group
14-19 %
decreased to a larger degree
#12
mycoprotein (MYC) as the primary source of dietary protein
decrease
n-3 fatty acids
MYC group
14-19 %
decreased to a larger degree
#13
Substituting meat/fish for mycoprotein twice daily for 1 week
no change
whole-body insulin sensitivity (IS)
-
-
did not modulate
#14
Substituting meat/fish for mycoprotein twice daily for 1 week
no change
glycaemic control
-
-
did not modulate
#15
Substituting meat/fish for mycoprotein twice daily for 1 week
decrease
plasma lipid composition
-
-
resulted in changes to
#16
Substituting meat/fish for mycoprotein twice daily for 1 week
decrease
circulating cholesterol-containing lipoproteins
-
-
reduction in
#17
Abstract

Mycoprotein consumption has been shown to improve acute postprandial glycaemic control and decrease circulating cholesterol concentrations. We investigated the impact of incorporating mycoprotein into the diet on insulin sensitivity (IS), glycaemic control and plasma lipoprotein composition. Twenty healthy adults participated in a randomised, parallel-group trial in which they consumed a 7 d fully controlled diet where lunch and dinner contained either meat/fish (control group, CON) or mycoprotein (MYC) as the primary source of dietary protein. Oral glucose tolerance tests were performed pre- and post-intervention, and 24 h continuous blood glucose monitoring was applied throughout. Fasting plasma samples were obtained pre- and post-intervention and were analysed using quantitative, targeted NMR-based metabonomics. There were no changes within or between groups in blood glucose or serum insulin responses, nor in IS or 24 h glycaemic profiles. No differences between groups were found for 171 of the 224 metabonomic targets. Forty-five lipid concentrations of different lipoprotein fractions (VLDL, LDL, intermediate-density lipoprotein and HDL) remained unchanged in CON but showed a coordinated decrease (7-27 %; all P < 0·05) in MYC. Total plasma cholesterol, free cholesterol, LDL-cholesterol, HDL2-cholesterol, DHA and n-3 fatty acids decreased to a larger degree in MYC (14-19 %) compared with CON (3-11 %; P < 0·05). Substituting meat/fish for mycoprotein twice daily for 1 week did not modulate whole-body IS or glycaemic control but resulted in changes to plasma lipid composition, the latter primarily consisting of a coordinated reduction in circulating cholesterol-containing lipoproteins.

Medical Subject Headings (MeSH)
Blood GlucoseBlood Glucose Self-MonitoringCholesterolDietary ProteinsFastingFemaleFish Proteins, DietaryFungal ProteinsGlucose Tolerance TestGlycemic ControlHealthy VolunteersHumansInsulinInsulin ResistanceLipidomicsLipoproteinsMaleMeat ProteinsPostprandial PeriodYoung Adult
Study Links
Quality Scores
Safety85
Efficacy65/10
Quality80/10
Citation Metrics
Total Citations28
Citations/Year7.0
Relative Citation Ratio3.14
NIH Percentile85.9%
Research Impact Scores
APT Score0.75
Weight Score2.66
Normalized Score0.76
Related Supplements
Daily mycoprotein consumption for 1 week does not affect ins... | Panacea Index